JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB179810

Anti-LOXL2 抗体 [EPR12733] - C-terminal

Anti-LOXL2 antibody [EPR12733] - C-terminal

4

(6 Reviews)

|

(18 Publications)

Rabbit Recombinant Monoclonal LOXL2 antibody. C-terminal. Suitable for WB and reacts with Human samples. Cited in 18 publications.

別名を表示する

Lysyl oxidase homolog 2, Lysyl oxidase-like protein 2, Lysyl oxidase-related protein 2, Lysyl oxidase-related protein WS9-14, LOXL2

4 Images
Western blot - Anti-LOXL2 antibody [EPR12733] - C-terminal (AB179810)
  • WB

Lab

Western blot - Anti-LOXL2 antibody [EPR12733] - C-terminal (AB179810)

Lanes 1-4 : Merged signal (red and green). Green - ab179810 observed at 105 kDa. Red - loading control, ab8245 observed at 37 kDa.

ab179810 Anti-LOXL2 antibody [EPR12733] - C-terminal was shown to specifically react with LOXL2 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab264807 (knockout cell lysate ab257166) was used. Wild-type and LOXL2 knockout samples were subjected to SDS-PAGE. ab179810 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 500 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 10000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810) at 1/500 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

LOXL2 knockout HeLa cell lysate at 20 µg

Lane 3:

HeLa treated with 0.5nM CoCl2 for 6 hours whole cell lysate at 20 µg

Lane 4:

Untreated HeLa cell lysate at 20 µg

Predicted band size: 87 kDa

Observed band size: 105 kDa

false

Western blot - Anti-LOXL2 antibody [EPR12733] - C-terminal (AB179810)
  • WB

Lab

Western blot - Anti-LOXL2 antibody [EPR12733] - C-terminal (AB179810)

Lanes 1-4 : Merged signal (red and green). Green - ab179810 observed at 105 kDa. Red - loading control, ab8245 observed at 37 kDa.

ab179810 Anti-LOXL2 antibody [EPR12733] - C-terminal was shown to specifically react with LOXL2 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab261804 (knockout cell lysate ab257168) was used. Wild-type and LOXL2 knockout samples were subjected to SDS-PAGE. ab179810 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 500 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (ab216776) secondary antibodies at 1 in 10000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810) at 1/500 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

LOXL2 knockout HeLa cell lysate at 20 µg

Lane 4:

Untreated HeLa cell lysate at 20 µg

Predicted band size: 87 kDa

Observed band size: 105 kDa

false

Western blot - Anti-LOXL2 antibody [EPR12733] - C-terminal (AB179810)
  • WB

Lab

Western blot - Anti-LOXL2 antibody [EPR12733] - C-terminal (AB179810)

Lanes 1-4 : Merged signal (red and green). Green - ab179810 observed at 105 kDa. Red - loading control, ab8245 observed at 37 kDa.

ab179810 Anti-LOXL2 antibody [EPR12733] - C-terminal was shown to specifically react with LOXL2 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab261804 (knockout cell lysate ab257168) was used. Wild-type and LOXL2 knockout samples were subjected to SDS-PAGE. ab179810 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 500 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (ab216776) secondary antibodies at 1 in 10000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810) at 1/500 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

LOXL2 knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human LOXL2 knockout HeLa cell line (<a href='/products/cell-lines/human-loxl2-knockout-hela-cell-line-ab261804'>ab261804</a>)

Lane 3:

HeLa treated with 0.5nM CoCl2 for 6 hours whole cell lysate at 20 µg

Lane 4:

Untreated HeLa cell lysate at 20 µg

Predicted band size: 87 kDa

Observed band size: 105 kDa

false

Western blot - Anti-LOXL2 antibody [EPR12733] - C-terminal (AB179810)
  • WB

Lab

Western blot - Anti-LOXL2 antibody [EPR12733] - C-terminal (AB179810)

Exposure time :

Lane 1-3 : 3min
Lane 4 : 1min

Blocking/Diluting buffer and concentration 5% NFDM /TBST

MCF-7 lack LOXL2 expression (PMID : 19330836, PMID : 12154058 and PMID : 27655685)

Lanes 1, 2 and 4:

Western blot - Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810) at 1/1000 dilution

Lane 3:

Western blot - Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810) at 1/200 dilution

Lane 1:

MCF-7 (Human breast carcinoma) whole cell lysate at 10 µg

Lane 2:

MDA-MB-435 (Human ductal carcinoma) whole cell lysate at 10 µg

Lane 3:

A431 (Human epidermoid carcinoma) whole cell lysate at 10 µg

Lane 4:

U87-MG (Human glioblastoma) whole cell lysate at 10 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Predicted band size: 87 kDa

Observed band size: 105 kDa

false

関連する標識済み抗体及び組成の異なる製品 (2)

  • HRP

    HRP Anti-LOXL2 antibody [EPR12733] - C-terminal

  • Carrier free

    Anti-LOXL2 antibody [EPR12733] - BSA and Azide free

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

EPR12733

アイソタイプ

IgG

キャリアフリー

No

交差種

Human

アプリケーション

WB

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

特異性

Our lab has been unable to use this product successfully in IHC-P and so we cannot guarantee that it will work in this application. However, some customers have been successful with this antibody in IHC-P.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/200 - 1/1000", "WB-species-notes": "<p></p>" }, "Mouse": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Rat": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" } } }

製品の詳細

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein A
バッファー組成
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

ターゲットの情報

Mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine) (PubMed : 27735137). Acts as a transcription corepressor and specifically mediates deamination of trimethylated 'Lys-4' of histone H3 (H3K4me3), a specific tag for epigenetic transcriptional activation (PubMed : 27735137). Shows no activity against histone H3 when it is trimethylated on 'Lys-9' (H3K9me3) or 'Lys-27' (H3K27me3) or when 'Lys-4' is monomethylated (H3K4me1) or dimethylated (H3K4me2) (PubMed : 27735137). Also mediates deamination of methylated TAF10, a member of the transcription factor IID (TFIID) complex, which induces release of TAF10 from promoters, leading to inhibition of TFIID-dependent transcription (PubMed : 25959397). LOXL2-mediated deamination of TAF10 results in transcriptional repression of genes required for embryonic stem cell pluripotency including POU5F1/OCT4, NANOG, KLF4 and SOX2 (By similarity). Involved in epithelial to mesenchymal transition (EMT) via interaction with SNAI1 and participates in repression of E-cadherin CDH1, probably by mediating deamination of histone H3 (PubMed : 16096638, PubMed : 24414204, PubMed : 27735137). During EMT, involved with SNAI1 in negatively regulating pericentromeric heterochromatin transcription (PubMed : 24239292). SNAI1 recruits LOXL2 to pericentromeric regions to oxidize histone H3 and repress transcription which leads to release of heterochromatin component CBX5/HP1A, enabling chromatin reorganization and acquisition of mesenchymal traits (PubMed : 24239292). Interacts with the endoplasmic reticulum protein HSPA5 which activates the IRE1-XBP1 pathway of the unfolded protein response, leading to expression of several transcription factors involved in EMT and subsequent EMT induction (PubMed : 28332555). Involved in E-cadherin repression following hypoxia, a hallmark of EMT believed to amplify tumor aggressiveness, suggesting that it may play a role in tumor progression (PubMed : 20026874). When secreted into the extracellular matrix, promotes cross-linking of extracellular matrix proteins by mediating oxidative deamination of peptidyl lysine residues in precursors to fibrous collagen and elastin (PubMed : 20306300). Acts as a regulator of sprouting angiogenesis, probably via collagen IV scaffolding (PubMed : 21835952). Acts as a regulator of chondrocyte differentiation, probably by regulating expression of factors that control chondrocyte differentiation (By similarity).
See full target information LOXL2

文献 (18)

Recent publications for all applications. Explore the full list and refine your search

American journal of physiology. Heart and circulatory physiology 327:H642-H659 PubMed39028284

2024

Sex differences and role of lysyl oxidase-like 2 in angiotensin II-induced hypertension in mice.

Applications

Unspecified application

Species

Unspecified reactive species

Huilei Wang,Marta Martinez Yus,Travis Brady,Rira Choi,Kavitha Nandakumar,Logan Smith,Rosie Jang,Bulouere Princess Wodu,Jose Diego Almodiel,Laila Stoddart,Deok-Ho Kim,Jochen Steppan,Lakshmi Santhanam

Journal of thoracic disease 16:581-592 PubMed38410543

2024

Increased LOXL2 expression is related to poor prognosis in lung squamous cell carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Lei Cao,Jian Zhong,Zicheng Liu,Jie Jiang,Chenyao Zhu,Feng Liu,Bo Wang

Physiological reports 11:e15656 PubMed37038896

2023

Neonatal exposure to hypoxia induces early arterial stiffening via activation of lysyl oxidases.

Applications

Unspecified application

Species

Unspecified reactive species

Jochen Steppan,Kavitha Nandakumar,Huilei Wang,Rosie Jang,Logan Smith,Sara Kang,William Savage,Maria Bauer,Rira Choi,Travis Brady,Bulouere Princess Wodu,Susanna Scafidi,Joseph Scafidi,Lakshmi Santhanam

Communications biology 6:375 PubMed37029269

2023

Lysyl oxidase-like 2 processing by factor Xa modulates its activity and substrate preference.

Applications

Unspecified application

Species

Unspecified reactive species

Huilei Wang,Alan Poe,Marta Martinez Yus,Lydia Pak,Kavitha Nandakumar,Lakshmi Santhanam

Frontiers in oncology 12:974614 PubMed36185284

2022

A novel epithelial-mesenchymal transition (EMT)-related gene signature of predictive value for the survival outcomes in lung adenocarcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Yimeng Cui,Xin Wang,Lei Zhang,Wei Liu,Jinfeng Ning,Ruixue Gu,Yaowen Cui,Li Cai,Ying Xing

Translational cancer research 11:2013-2025 PubMed35966289

2022

Inhibitory effects of LOXL2 knockdown on cellular functions of liver cancer stem cells.

Applications

Unspecified application

Species

Unspecified reactive species

Na Li,Huan Gu,Liu Liu,Xiao-Li Zhang,Qiu-Luo Cheng,Ying Zhu

Communications biology 4:840 PubMed34226627

2021

An in situ activity assay for lysyl oxidases.

Applications

Unspecified application

Species

Unspecified reactive species

Huilei Wang,Alan Poe,Lydia Pak,Kavitha Nandakumar,Sandeep Jandu,Jochen Steppan,Reik Löser,Lakshmi Santhanam

Molecular medicine reports 24: PubMed34013363

2021

Phenylethanol glycosides from Herba Cistanche improve the hypoxic tumor microenvironment and enhance the effects of oxaliplatin via the HIF‑1α signaling pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Limei Wen,Junping Hu,Jiawei Zhang,Jianhua Yang

Frontiers in immunology 11:480 PubMed32296422

2020

LOXL2 Inhibition Paves the Way for Macrophage-Mediated Collagen Degradation in Liver Fibrosis.

Applications

Unspecified application

Species

Unspecified reactive species

Mordehay Klepfish,Tamar Gross,Milena Vugman,Nikolaos A Afratis,Sapir Havusha-Laufer,Eli Brazowski,Inna Solomonov,Chen Varol,Irit Sagi

Oncology reports 43:1641-1649 PubMed32323822

2020

LOXL2 upregulates hypoxia‑inducible factor‑1α signaling through Snail‑FBP1 axis in hepatocellular carcinoma cells.

Applications

Unspecified application

Species

Unspecified reactive species

Zhiyong Fan,Wei Zheng,Hui Li,Wujun Wu,Xiaogang Liu,Zhongjie Sun,Haitian Hu,Lixue Du,Qingan Jia,Qingguang Liu
View all publications

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com